Methylnaltrexone: Treatment for opioid-induced constipation

American Journal of Hospice and Palliative Medicine

Volumn 28, Issue 1, 2011, Pages 59-61

  Licup, Nerissa ^a   Baumrucker, Steven J ^a,b  

^a East Tennessee State University   (United States)

^b USA   (United States)

Author keywords

constipation; methylnaltrexone; opioid induced bowel dysfunction; palliative care; treatment

Indexed keywords

17 METHYLNALTREXONE; DRUG DERIVATIVE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CONSTIPATION; DEFECATION; DRUG EFFECT; HUMAN; INTRACTABLE PAIN; METHODOLOGY; PALLIATIVE THERAPY; QUALITY OF LIFE;

ANALGESICS, OPIOID; CONSTIPATION; DEFECATION; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN, INTRACTABLE; PALLIATIVE CARE; QUALITY OF LIFE; QUATERNARY AMMONIUM COMPOUNDS;

EID: 78751560384     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909110373507     Document Type: Article

References (17)

1. Panchal SJ, Muller-Schwefe P., Wurzelmann JI Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Prac. 2007;61(7):1181-1187.
2. Schug S., Zech D., Grond S., Jung H., Meuser T., Stobbe B. A long-term survey of morphine in cancer patients. J Pain Symptom Manage. 1992;7(5):259-266.
3. McMillan SC Assessing and managing opioid-induced constipation in adults with cancer. Cancer Control. 2004;11(3):3-9.
4. Becker G., Galandi D., Blum HE Peripherally acting opioid antagonists in the treatment of opioid-related constipation:a systematic review. J Pain Symptom Manage. 2007;34(5):547-565.
5. Yuan C., Foss J., O'Connor M. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283(3):367-372.
6. Berde C., Nurko S. Opioid side effects-mechanism based therapy. NEJM. 2008;358(22):2400-2402.
7. Pappagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl): 11S-18S.
8. McMillan S. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3):3-9.
9. Clemens KE, Klaschik E. Management of constipation in palliative care patients. Curr Opin Support Palliat Care. 2008;2(1): 22-27.
10. Klaschik E., Nauck F. Constipation-modern laxative therapy. Support Care Cancer. 2003;11(11):679-685.
11. Lacy B., Levy LC Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-364.
12. Fei G., Raehal K., Liu S., Qu M., Sun X., Wang GD, Wang XY, Xia Y., Schmid CL, Bohn LM, Wood JD Lubiprostone (SPI-0211) reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. [published online ahead of print April 20, 2010]. J Pharmacol Exp Ther. doi:10.1124/jpet.110.166116.
13. Sykes NP An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135-144.
14. Yuan C., Wei G., Foss JF, O'Connor M., Karrison T., Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized controlled trial. J.Pharmacol Exp Ther. 2002;300(1):118-123.
15. Portenoy R., Thomas J., Moehl Boatwright ML,et al.Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458-468.
16. Thomas J., Karver S. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22): 2332-2343.
17. Slatkin N., Thomas J., Lipman AG,et al.Methylnaltrexone for treatment of opioid-induced constipation in advanced illness. J Support Oncol. 2009; 7(1):39-46.